Niagen Bioscience, Inc. — Investor Relations & Filings
Filings indexed
954
across all filing types
Latest filing
2026-05-06
Regulatory Filings
Country
US
United States of America
Listing
US
NAGE
Niagen Bioscience, Inc. (formerly ChromaDex) is a bioscience company focused on the science of nicotinamide adenine dinucleotide (NAD+). The company aims to improve healthspan and support healthy aging by developing products that restore and optimize cellular NAD+ levels. Its core proprietary ingredient is Niagen®, a patented and clinically studied form of nicotinamide riboside (NR), a precursor to NAD+. Niagen® is the key component in the company's consumer dietary supplement brand, Tru Niagen®, and is also developed for the food, beverage, and pharmaceutical markets. The company's research is supported by numerous human clinical studies, a portfolio of over 50 owned and licensed patents, and collaborations with global research institutions.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - Niagen Bioscience, Inc. (0001386570) (Filer) | 2026-05-06 | English | |
| 8-K - Niagen Bioscience, Inc. (0001386570) (Filer) | 2026-03-19 | English | |
| 8-K - NIAGEN BIOSCIENCE, INC. (0001386570) (Filer) | 2026-02-26 | English | |
| 4 - NIAGEN BIOSCIENCE, INC. (0001386570) (Filer) | 2026-02-24 | English | |
| 4 - NIAGEN BIOSCIENCE, INC. (0001386570) (Filer) | 2026-02-24 | English | |
| 4 - NIAGEN BIOSCIENCE, INC. (0001386570) (Filer) | 2026-02-24 | English |
Browse filings by year
20 years- 2026 7 filings
- 2025 35 filings
- 2024 42 filings
- 2023 38 filings
- 2022 59 filings
- 2021 51 filings
- 2020 61 filings
- 2019 63 filings
- 2018 58 filings
- 2017 97 filings
- 2016 60 filings
- 2015 50 filings
- 2014 49 filings
- 2013 29 filings
- 2012 81 filings
- 2011 65 filings
- 2010 56 filings
- 2009 10 filings
- 2008 35 filings
- 2007 8 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 41996029 | 8-K - Niagen Bioscience, Inc. (0001386570) (Filer) | 2026-05-06 | English | ||
| 32986340 | 8-K - Niagen Bioscience, Inc. (0001386570) (Filer) | 2026-03-19 | English | ||
| 32891035 | 8-K - NIAGEN BIOSCIENCE, INC. (0001386570) (Filer) | 2026-02-26 | English | ||
| 32891032 | 4 - NIAGEN BIOSCIENCE, INC. (0001386570) (Filer) | 2026-02-24 | English | ||
| 32891033 | 4 - NIAGEN BIOSCIENCE, INC. (0001386570) (Filer) | 2026-02-24 | English | ||
| 32891034 | 4 - NIAGEN BIOSCIENCE, INC. (0001386570) (Filer) | 2026-02-24 | English | ||
| 29294558 | SCHEDULE 13G/A Filing | 2026-01-30 | English | ||
|
2025
8 filings
| |||||
| 12097869 | 8-K | 2025-12-22 | English | ||
| 12097870 | FORM 4 | 2025-11-17 | English | ||
| 12097871 | 8-K | 2025-11-06 | English | ||
| 12097875 | 8-K | 2025-11-04 | English | ||
| 12097872 | 10-Q | 2025-11-04 | English | ||
| 12097876 | Major Shareholding Notification 2025 | 2025-10-31 | English | ||
| 12097877 | 8-K | 2025-10-06 | English | ||
| 12097886 | REGISTRATION STATEMENT | 2025-08-08 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
Niagen Bioscience, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32418/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32418 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32418 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32418 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32418}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Niagen Bioscience, Inc. (id: 32418)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.